EMA/638299/2022

European Medicines Agency decision

P/0294/2022

of 10 August 2022

on the acceptance of a modification of an agreed paediatric investigation plan for brexpiprazole (Rxulti), (EMEA-001185-PIP01-11-M08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision
P/0294/2022

of 10 August 2022

on the acceptance of a modification of an agreed paediatric investigation plan for brexpiprazole (Rxulti), (EMEA-001185-PIP01-11-M08) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0160/2012 issued on 25 July 2012, the decision P/0243/2014 issued on 29 September 2014, the decision P/0215/2015 issued on 02 October 2015, the decision P/0234/2016 issued on 9 September 2016, the decision P/0316/2018 issued on 12 September 2018 and the decision P/0191/2021 issued on 10 May 2021,

Having regard to the application submitted by Otsuka Pharmaceutical Development & Commercialisation Europe GmbH on 24 June 2022 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 24 June 2022, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1, as amended.
[2] OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for brexpiprazole (Rxulti), film-coated tablet, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Otsuka Pharmaceutical Development & Commercialisation Europe GmbH, Europa-Allee 52, 60327 - Frankfurt am Main, Germany.

EMA/PDCO/181242/2022
Amsterdam, 24 June 2022

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001185-PIP01-11-M08

Scope of the application

Active substance(s):

Brexpiprazole

Invented name:

Rxulti

Condition(s):

Treatment of schizophrenia

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Otsuka Pharmaceutical Development & Commercialisation Europe GmbH

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Otsuka Pharmaceutical Development & Commercialisation Europe GmbH submitted to the European Medicines Agency on 17 March 2022 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0160/2012 issued on 25 July 2012, the decision P/0243/2014 issued on 29 September 2014, the decision P/0215/2015 issued on 02 October 2015, the decision P/0234/2016 issued on 9 September 2016, the decision P/0316/2018 issued on 12 September 2018 and the decision P/0191/2021 issued on 10 May 2021.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 25 April 2022.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of schizophrenia

The waiver applies to:

- all subsets of the paediatric population from birth to less than 13 years of age;
- film-coated tablet, oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s).

2. Paediatric Investigation Plan

2.1. Condition:

Treatment of schizophrenia

2.1.1. Indication(s) targeted by the PIP

Treatment of schizophrenia

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 13 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

2.1.4. Studies

Area	**Description**
Quality	Not applicable.
Non-clinical	Not applicable.
Clinical	**Study 1** Open-label, multicentre, sequential cohort dose escalation trial to assess the safety, tolerability and pharmacokinetics of oral brexpiprazole in adolescents with schizophrenia spectrum or psychotic disorder, and with other psychiatric disorders for which antipsychotic treatments are used in specialist child and adolescent psychiatry clinical practice (331-10-233) **Study 2** Randomised, multicentre, double-blind, placebo- and active-controlled trial to evaluate the short-term efficacy of brexpiprazole

	monotherapy for the treatment of adolescents with schizophrenia (331-10-234) **Study 3** Open-label, long-term, multicenter trial to evaluate the safety and tolerability of flexible-dose brexpiprazole as maintenance treatment in adolescents with schizophrenia (331-10-236) **Study 4** (added in procedure EMEA-001185-PIP01-M05) Extrapolation study based on data from brexpiprazole adult and paediatric trials and literature to support the maintenance of the antipsychotic effect of brexpiprazole in adolescents with schizophrenia (331-201-00185)

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety or efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2025
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of schizophrenia

Authorised indication(s):

- RXULTI is indicated for the treatment of schizophrenia in adult patients.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use